WellSpry Learn

Clinical guides.
Physician-reviewed.

Every article is written to answer the questions patients actually ask — and reviewed by board-certified physicians before publication. No wellness clichés. No generic advice. Just clinical depth.

GLP-1 Monitoring & Protocol
GLP-1 Protocol8 min readApril 2026

What Blood Tests Should You Get Before Starting GLP-1?

Standard pre-prescription bloodwork checks 12–15 markers. Here are the 10 biomarkers that actually matter before you start semaglutide or tirzepatide.

Read Article →
GLP-1 Monitoring10 min readApril 2026

GLP-1 and Muscle Loss: What's Happening and How to Prevent It

GLP-1 medications suppress appetite without distinguishing between fat and lean mass. Clinical trials show 25–39% of weight lost on semaglutide is lean mass.

Read Article →
GLP-1 Side Effects7 min readMarch 2026

GLP-1 Nausea: The B12 Protocol That Actually Works

GLP-1 causes nausea through delayed gastric emptying. B6 and B12 address this at the neurological level. The clinical case for proactive supplementation.

Read Article →
GLP-1 Monitoring9 min readMarch 2026

Muscle Loss on Semaglutide: What the Research Actually Shows

STEP trials show 25–39% of total weight loss is lean mass. Here is the mechanism and the evidence-based protocol to preserve muscle during active GLP-1 therapy.

Read Article →
GLP-1 Monitoring11 min readJanuary 2026

Wegovy vs Zepbound: A Biomarker-Based Comparison Guide

Semaglutide vs tirzepatide is not a simple choice. The right medication depends on your baseline biomarkers. Here is how to read the data.

Read Article →
GLP-1 Monitoring8 min readFebruary 2026

GLP-1 Side Effects and the Gut Microbiome

Nausea and constipation on GLP-1 therapy reflect specific microbiome disruptions. Here is the mechanism and the targeted intervention protocol.

Read Article →
GLP-1 Monitoring9 min readMarch 2026

The Gut Microbiome-GLP-1 Connection

GLP-1 is also produced by your gut bacteria. Microbiome composition explains why some patients respond dramatically to GLP-1 therapy and others barely respond.

Read Article →
Testing & Longevity
Testing10 min readMarch 2026

What to Test Before Starting GLP-1 Therapy: The Complete Pre-Treatment Panel

Starting GLP-1 without baseline labs is like measuring weight loss without a starting weight. Here are the 14 essential biomarkers before your first injection.

Read Article →
Testing8 min readFebruary 2026

HOMA-IR Explained: What Your Insulin Resistance Score Actually Means

HOMA-IR from two fasting values predicts GLP-1 response, cardiovascular risk, and metabolic disease progression. Here is how to interpret your score.

Read Article →
Longevity11 min readJanuary 2026

Biological Age Testing Explained: Epigenetic Clocks, Telomeres, and What Tests Measure

Most consumer biological age tests use first-generation clocks. Here is a clear-eyed breakdown of GrimAge, PhenoAge, and telomere length — with the evidence behind each.

Read Article →
Peptide Protocols & Legal Updates
Peptides9 min readApril 2026

Peptide Reclassification 2026: What It Means for Your Protocol

The FDA reclassification affects which peptides can be legally compounded. Here is exactly what changed and what is still available.

Read Article →
Peptides7 min readFebruary 2026

BPC-157 Legal Status 2026: What the FDA Reclassification Actually Means

The FDA Category 2 designation for BPC-157 is not a ban. Here is the regulatory framework and the current legal pathway.

Read Article →
Peptides12 min readJanuary 2026

CJC-1295/Ipamorelin Protocol: Dosing, Timing, and What the Research Shows

The most prescribed growth hormone secretagogue combination. Clinical data, dosing protocol, timing science, and monitoring markers.

Read Article →
Peptides8 min readFebruary 2026

Selank: The Anxiolytic Peptide — Mechanism, Dosing, and Clinical Evidence

Clinical trials show equivalent anxiolytic effect to diazepam with no sedation or addiction potential. Here is the mechanism and protocol.

Read Article →
Peptides7 min readMarch 2026

AOD-9604: The Fat Loss Fragment — What It Does and What the Research Shows

hGH fragment 176-191 produces targeted lipolysis without IGF-1 elevation, glucose impairment, or the risks of full synthetic HGH.

Read Article →
Peptides8 min readMarch 2026

Thymosin Alpha-1: The Immune Modulator — Evidence, Dosing, and Who It's For

Approved in 70+ countries for viral infections and immunodeficiency. How it addresses immunosenescence in longevity and GLP-1 protocols.

Read Article →
Ready to go beyond the reading?

Take the free 3-minute quiz and get a personalised plan based on your goals and symptoms. The full picture comes from your biomarkers.

Get My Free Blueprint →